In Reply to ‘Febuxostat for Asymptomatic Hyperuricemia in CKD' and ‘Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia’

We agree with Mome and Bakinde1 that our study has a lack of generalizability because the population was solely from Eastern India. However, of note, Goicoechea et al2 have demonstrated the effects of allopurinol in a Spanish cohort. Significance tests of baseline differences have been discouraged by the CONSORT statement,3 and it has been suggested that such testing does not provide an appropriate criterion to assess the effect of imbalance on outcome or the decision to adjust for baseline variables.